UBS Oncology Impact Fund L.P. - Insider Non-Derivative Transactions at Werewolf Therapeutics, Inc. (HOWL) - (SEC)

Updated on March 12, 2026.

According to recent SEC insider information filed on Dec 1, 2025, UBS Oncology Impact Fund L.P.'s relationship to Werewolf Therapeutics, Inc. (HOWL) is TenPercentOwner, and currently has 4,983,843 shares of Common Stock.

The chart below shows the number of shares owned, and the table shows the recent insider transactions.

You can see similar information for other HOWL insiders.

Related Topics: SEC Topic List.

Data Source: SEC.

UBS Oncology Impact Fund L.P. - Insider Non-Derivative Transactions of HOWL Common Stock

UBS Oncology Impact Fund L.P. - Insider Non-Derivative Transactions at HOWL

Items per page:

0 of 0

Date	Transaction	No. of Shares	Price Per Share	Shares Owned After Transactions
Dec 2, 2025	Sell -- (Common Stock)	60917	0.94	4983843
Nov 29, 2025	Sell -- (Common Stock)	20277	0.99	5044760
Nov 27, 2025	Sell -- (Common Stock)	60733	0.98	5065037
Nov 13, 2025	Sell -- (Common Stock)	40669	1.09	5691191
Nov 12, 2025	Sell -- (Common Stock)	55810	1.14	5731860
Nov 11, 2025	Sell -- (Common Stock)	48570	1.18	5787670
Nov 8, 2025	Sell -- (Common Stock)	68480	1.11	5836240
Oct 30, 2025	Sell -- (Common Stock)	134240	1.55	6442653
Oct 29, 2025	Sell -- (Common Stock)	69068	1.64	6576893
Oct 28, 2025	Sell -- (Common Stock)	72709	1.72	6645961